IGI Logo

Marksans Pharma is currently trading at Rs. 101.18, up by 7.77 points or 8.32% from its previous closing of Rs. 93.41 on the BSE.

The scrip opened at Rs. 93.42 and has touched a high and low of Rs. 102.90 and Rs. 93.42 respectively. So far 530856 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 102.90 on 12-Jul-2023 and a 52 week low of Rs. 45.65 on 11-Oct-2022.

Last one week high and low of the scrip stood at Rs. 102.90 and Rs. 90.85 respectively. The current market cap of the company is Rs. 4585.11 crore.

The promoters holding in the company stood at 43.85%, while Institutions and Non-Institutions held 16.58% and 39.58% respectively.

Marksans Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter (OTC) bioequivalent of Advil Dual Action Tablets 250 mg/125 mg.

The Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) are bioequivalent to the reference listed drug (RLD), Advil Dual Action of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. Advil Dual Action was first available as an over-the-counter drug in 2020.

The pivotal approval, Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen and acetaminophen. Ibuprofen works through the body targeting pain at the source while Acetaminophen blocks pain signal to the brain. The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief. The company plans to launch the product immediately.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.